Number of the records: 1
XIII. Výročný kongres Medzinárodnej spoločnosti pre farmakoekonomiku a výskum výsledkov. Toronto, 3.-7.V.2008
Title XIII. Výročný kongres Medzinárodnej spoločnosti pre farmakoekonomiku a výskum výsledkov. Toronto, 3.-7.V.2008 Document part Časť 2.. Diabetológia, kardiológia, neurológia Author info Lenka Petrová, Veronika Dubajová, Viliam Foltán Author Petrová Lenka
Co-authors Dubajová Veronika
Foltán Viliam 1946-
Note Voľný preklad z kongresových materiálov Sign. C 3079 Source Farmakoekonomika a lieková politika : oficiálny časopis Slovenskej spoločnosti pre farmakoekonomiku. - ISSN 1336-7021. - Nové Mesto nad Váhom : TISING , 2008 . - Roč. 4, č. 3 (2008), s. 27-28 a 30-53 Contains also Cost-effectiveness of drug therapy for diabetes mellitus - a systematic review / Y. J. Zhang -- Cost and effectiveness of insulin vs rosiglitazone in type II diabetes after metformin monotherapy failure / J. Skoupá -- Comparison of resource utilization (RU) and cost in drug naive type 2 diabetes (T2D) patients treated with rosiglitazone (RSG) verzus sulfonylurea (SU) monotherapy / A. Gosselin -- Hagedorn in type 1 diabetes patients in the Czech setting - data from PREDICTIVE™ study / J. P. Clegg -- Cost-effectiveness of insulin detemir compared to NPH insulin for type 2 diabetes mellitus (T2DM) in the Canadian payer setting: modeling analysis using an observational study / M. E. Minshall -- Clinical and economic characteristics of patienta with diabetic neuropathy / Y. Zhao -- Medical care of patients with diabetic neuropathy: impact of type 1 diabetes and presence of other diabetes-related complications / Y. Zhao -- Cost-effectiveness of insulin detemir versus NPH insulin for type 1 diabetes patients treated with basal-bolus therapy in Portugal / C. Silva -- A modelled cost-effectiveness analysis of switching patients with poorly controlled type 2 diabetes to insulin detemir from oral antidiabetics or NPH in the Austrian setting; data from the PREDICTIVE study / L. Stechemesser -- Exenatide utilization and effectiveness in a health plan population / B. Schroeder -- Canadian cost utility analysis comparing exenatide versus insulin glargine in patients with type 2 diabetes / D. Coyle -- Lost productivity associated with type 1 and type 2 diabetes in a commercially insured population / E. Durden -- Systematic review of adherence, compliance and Quality of life in type 2 diabets patients / J. B. Kumar -- Comparison of healthcare utilization and cost in type 2 diabetes patients initiating analog and human insulins / J. Margolis -- Likelihood and cost of adverse events in atrial fibrillation are associated with choice of acute conversion therapy / M. Belz -- Economic evaluation of atosiban versus beta-mimetics in the treatment of preterm labour in Germany / J. Wex -- Evaluation of resistant hypertension in a usual-care setting / C. McAdam-Marx -- Blood pressure success zone longitudinal study of succes (BPSZ - BLISS): an observational, multicenter study of the impact of the BPSZ educational program on blood pressure control, perzistence, compliance and treatment satisfaction. Enrollment metrics and baseline cohort characteristics / K. A. Payne l -- A modified RxRisk-V comorbidity index predicts adherence with lipid lowering therapy (LLT) / S. R. Ghate -- Assessment and quantification of the benefit risk ratio of rosuvastatin and atorvastatin from a meta-analysis of head-to-head randomised controlled trials / J. Wlodarczyk -- The cost and effectiveness of adherence-improving interventions for lipid-lowering and antihypertensive drugs / R. H. Chapman -- The cost-utility of aliskiren in the treatment of mild to moderate hypertension. A Canadian healthcare system perspective / A. Lee -- A flexible tool to estimate medical care costs for study events in cardiovascular endpoints trials / D. Thompson -- The impact of targeted member education on choice of preferred statin therapy after a formulary change / E. Cox -- Begian budget impact analyses of aliskiren (Tekturna®/Rasilez®) in hypertension / P. Lecomte -- The cost-effectiveness of aliskiren as add on to losartan and optimal antihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the UK setting / J. L. Palmer -- Patient adherence to cholesterol treatment (PACT): Canadian physician and patient perspectives / B. Beamer -- Clinical determinants of satisfaction and health related quality of life in patients with cardiac disease and dyslipidemia / A. D. Raju -- Bosentan is a cost-effective treatment for UK patients with pulmonary arterial hypertension of WHO class III / M. Stevenson -- Clopidogrel is cost-effective compared with aspirin in UK patients with a myocardial infarction WHO subsequently suatain an ischaemic stroke or diagnosis of peripheral arterial disease / M. Stevenson -- Impact of adoption of new antihypertensive drugs on the healthcare utilization in hypertensive patients / A. Ganguli -- Impact of prescription copay on adherence to renin-angiotensin system agents in heart failure patients / Xiaolan Ye -- Physical and patient-reported outcomes in multiple sclerosis / S. Kirzinger -- Migraine suffers show significant health care utilization and expenditures / R. G. Iyer -- Modeling the impact of a fixed-dose combination of sumatriptan and naproxen sodium on triptan consumption in a US managed care population / T. W. Smith -- Severity of illness among persons with multiple sclerosis: an analysis of cost quintiles / N. L. Kleinman -- Prevalence and costs of comorbidities among persons with and without multiple sclerosis: an analysis of the AHRQ major and specific diagnostic categories / R. A. Brook -- Relationship between adherence to multiple sclerosis medications and total health care costs / N. G. Khandelwal -- Exploring the impact of different dispensing systems on medication compliance and persistence in multiple sclerosis patients using pharmacy claims data / J. Tang -- Cost of disability and medically-related absenteeism among employees with multiple sclerosis / H. G. Birnbaum -- Comparison of compliance and persistence with immunomodulating agents for multiple sclerosis in a commercially insured population / T. Shea -- Association between change in overall quality of life (QoL), disease level and functional status since natalizumab initiation / K. Rajagopalan -- Switching to high-dose, high-frequency interferons or natalizumab in patients with multiple sclerosis: a cost-effectiveness analysis / C. Fischer -- Medical costs associated with treatment change in multiple sclerosis / B. L. Nordstrom -- Impact of non-adherence to antiepileptic drugs on morbidity: results from a medicaid population / J. R. Weiner -- The concentration and persistence of health care expenditures and prescription drug expenditures in patients with Alzheimer's disease / Pei-Jung Lin Event keywords International Society for Pharmacoeconomics and Outcomes Research. Annual international meeting ( 13. : 2008 : Toronto, Kanada ) MeSH Subject farmakoekonomika
náklady a analýza nákladov
diabetes mellitus : ekonomika
komplikácie diabetu : ekonomika
choroby kardiovaskulárne : ekonomika
choroby nervového systému : ekonomika
farmakoterapia : ekonomika
Extended Title Trinásty Výročný kongres Medzinárodnej spoločnosti pre farmakoekonomiku a výskum výsledkov. Toronto, 3.-7.V.2008 Language Slovak Country Slovak Republic Document kind Rozpis článkov z periodík Database ARTICLES 
article
Number of the records: 1